Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group

Am J Hematol. 2019 Jul;94(7):E183-E185. doi: 10.1002/ajh.25480. Epub 2019 Apr 11.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Multicenter Study

MeSH terms

  • Adenine / analogs & derivatives
  • Autoimmune Diseases* / drug therapy
  • Autoimmune Diseases* / mortality
  • Disease-Free Survival
  • Female
  • Hematologic Diseases* / drug therapy
  • Hematologic Diseases* / mortality
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
  • Leukemia, Lymphocytic, Chronic, B-Cell* / mortality
  • Male
  • Piperidines
  • Purines / administration & dosage*
  • Pyrazoles / administration & dosage*
  • Pyrimidines / administration & dosage*
  • Quinazolinones / administration & dosage*
  • Survival Rate

Substances

  • Piperidines
  • Purines
  • Pyrazoles
  • Pyrimidines
  • Quinazolinones
  • ibrutinib
  • Adenine
  • idelalisib